Midomafetamine

Psychedelic drugs are nearing prescription for European patients with mental health issues, but hurdles remain. Research on psilocybin and MDMA is ongoing, with potential to treat conditions like depression and addiction. Controversy and challenges in study replication persist, but larger-scale studies and advances in brain scan technology are providing clearer insights. The first psychedelic to hit the European market may be from UK-based Compass Pathways, which is testing psilocybin for treatment-resistant depression. The psychedelic movement faces setbacks, such as US regulators rejecting MDMA for PTSD, which could delay access in Europe.

Two men, Susheel Kumar and Palukuri Deepak, were arrested with 27 grams of MDMA by the Excise State Task Force (STF) at Jambagh flower market. Supplier Praveen Singh Rav from Bengaluru was identified, along with associates V. Ramesh and Charan. Customers Hitesh, Shaik Mohammad, and Bobby were found to be making online payments for the contraband. Susheel transported MDMA to Hyderabad via private buses, selling it at double the price.

Demand for naloxone doubled as stimulant and hallucinogenic users, fearing laced narcotics, sought the drug. Health authorities urge all drug users to carry naloxone due to synthetic opioids in illicit drugs. The Take Home Naloxone program saw a surge in supply, from 110,976 units in 2022-2023 to 243,248 in 2023-2024.

Despite MDMA-assisted therapy (MDMA-AT) showing promise for PTSD, its inaccessibility due to time, cost, and operational challenges makes it impractical for widespread use. The focus now shifts to FDA-cleared, neuroscience-based technologies that offer scalable, cost-effective PTSD treatments, addressing the critical need for accessible mental health care.

John Krystal, MD discusses the potential of ketamine and other psychedelics in treating psychiatric disorders, highlighting the antidepressant effects of ketamine and the development of drug combinations at Freedom Biosciences to extend ketamine's efficacy. The FDA's recent decision on MDMA-assisted therapy for PTSD has spurred further research into psychedelics for conditions like major depression, PTSD, migraine, and substance use disorders.

FDA rejection of Lykos Therapeutics' MDMA application for PTSD treatment led to layoffs and CEO change, opening opportunities for PharmAla Biotech to supply MDMA for clinical trials. PharmAla focuses on non-U.S. markets and plans physician education for MDMA use in PTSD and other mental health conditions.

Greenlane Holdings, Inc. (NASDAQ: GNLN) plans to launch fentanyl, xylazine, and drink spike detection test strips under the Safety Strips brand, available from September 25th. The global opioid overdose treatment market is expected to reach $1.54 billion in 2024, with a projected CAGR of 7.2% through 2034.

Congressional lawmakers seek public input on creating a regulatory framework for psychedelic therapies, emphasizing the need for inclusive, responsible, and ethical use, and considering the cultural practices of indigenous communities.

Drug shortages, including critical antibiotics, fever medications, and cancer treatments, highlight global supply chain issues and the need for improved health policies. The FDA rejected MDMA for PTSD treatment, with psilocybin next for treatment-resistant depression. Companion apps tested for alleviating loneliness. Advanced Clinical named one of Crain's Best Places to Work in Chicago 2024. Luke Forsthoefel's thought leadership article published in Pharmaceutical Executive magazine.

Safe Supply Streaming's portfolio company, Safety Strips, launches affordable drug detection strips to combat fentanyl, xylazine, and drink spiking, in response to new California legislation. The strips will be available via Greenlane Holdings' distribution channels starting September 25, 2024.